{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"Abbreviation","name":"PARPi-FL"},{"type":"Synonym","name":"fluorescent PARPi binding imaging agent PARPi-FL"},{"type":"Synonym","name":"olaparib-BODIPY FL"},{"type":"Synonym","name":"fluorescent PARP1 inhibitor PARPi-FL"},{"type":"Synonym","name":"AZD2281-BODIPY FL"},{"type":"Synonym","name":"BODIPY-modified olaparib fluorescent imaging agent"},{"type":"CASRegistryName","name":"1380359-84-1"},{"type":"CodeName","name":"ABY-029"},{"type":"ChemicalStructureName","name":"boron, (4-((3-((4-(3-(5-((3,5-dimethyl-2H-pyrrol-2-ylidene-kappaN)methyl)-1H-pyrrol-2-yl-kappaN)-1-oxopropyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinonato)difluoro-, (T-4)-"}],"definition":{"html":"A poly (ADP-ribose) polymerase type 1 (PARP1) fluorescence imaging agent based on the PARP1 inhibitor olaparib, in which the cyclopropane group of olaparib is replaced by the green fluorescent dye boron-dipyrromethene (BODIPY) fluorophore (FL), with potential fluorescent imaging activity. Upon administration of the fluorescent PARP1 inhibitor PARPi-FL, the olaparib binding moiety specifically targets and binds to PARP1, which is often overexpressed on cancer cells. Upon fluorescent imaging, the PARP1-expressing cancer cells can be visualized. PARP1, the nuclear enzyme that catalyzes post-translational ADP-ribosylation of nuclear proteins, is activated by single-strand (SS) DNA breaks and overexpressed in certain tumor cells; it plays a key role in DNA repair, tumor cell resistance and survival.","text":"A poly (ADP-ribose) polymerase type 1 (PARP1) fluorescence imaging agent based on the PARP1 inhibitor olaparib, in which the cyclopropane group of olaparib is replaced by the green fluorescent dye boron-dipyrromethene (BODIPY) fluorophore (FL), with potential fluorescent imaging activity. Upon administration of the fluorescent PARP1 inhibitor PARPi-FL, the olaparib binding moiety specifically targets and binds to PARP1, which is often overexpressed on cancer cells. Upon fluorescent imaging, the PARP1-expressing cancer cells can be visualized. PARP1, the nuclear enzyme that catalyzes post-translational ADP-ribosylation of nuclear proteins, is activated by single-strand (SS) DNA breaks and overexpressed in certain tumor cells; it plays a key role in DNA repair, tumor cell resistance and survival."},"drugInfoSummaryLink":null,"nciConceptId":"C133717","nciConceptName":"Boron-dipyrromethene-modified Olaparib Fluorescent Imaging Agent","termId":788166,"name":"boron-dipyrromethene-modified olaparib fluorescent imaging agent","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"boron-dipyrromethene-modified-olaparib-fluorescent-imaging-agent"},{"aliases":[{"type":"Synonym","name":"PARP inhibitor AZD2281"},{"type":"CodeName","name":"AZD2281"},{"type":"CodeName","name":"KU-0059436"},{"type":"USBrandName","name":"Lynparza"},{"type":"CASRegistryName","name":"763113-22-0"},{"type":"CodeName","name":"AZD 2281"},{"type":"CodeName","name":"AZD-2281"},{"type":"ForeignBrandName","name":"Olanib"},{"type":"ForeignBrandName","name":"Olaparix"}],"definition":{"html":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","text":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/olaparib","text":"Olaparib"},"nciConceptId":"C71721","nciConceptName":"Olaparib","termId":560191,"name":"olaparib","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"olaparib"}],"links":null}